Andexxa (andexanet) is a treatment currently used when the reversal of anticoagulation is needed for life-threatening or uncontrolled bleeding in patients who are using Eliquis (apixaban) or Xarelto (rivaroxaban) at the time. Andexxa drug injury lawsuits for patients who developed blood clots involving a pulmonary embolism (PE) or deep vein … [Read more...]
Andexxa Clotting-Related Deaths and Andexxa Blood Clots
The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee recently discussed the increased risk of Andexxa clotting-related deaths and Andexxa blood clots seen in the ANNEXA-I trial done for Andexxa, compared with a standard of care reversal agent. This Andexxa Advisory Committee considered the current drug safety profile of Andexxa in … [Read more...]
Blood Clots When Using Wegovy, Rybelsus, or Ozempic
Drug injury lawsuits that might be filed against the pharmaceutical company Novo Nordisk involving blood clots when using Wegovy, Rybelsus, or Ozempic are somewhat like the federal court Wegovy/Rybelsus/Ozempic MDL lawsuits involving gastrointestinal and stomach problems because they would involve similar — but different — liability issues, such … [Read more...]
Wegovy / Rybelsus / Ozempic DVT Blood Clots Side Effects Cases
Wegovy, Rybelsus, and Ozempic DVT blood clots side effects have not received as much attention as adverse event reports that involve severe stomach conditions such as gastroparesis, gastric stasis, and stomach paralysis. Ozempic, Wegovy, and Rybelsus are three popular GLP-1 receptor agonists containing semaglutide that are increasingly used as … [Read more...]
Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq
We continue to monitor the pharmaceutical regulatory sector as well as the medical literature for developments as regards the increased risks of cancers, blood clots, heart problems, and deaths associated with Xeljanz, Olumiant, and Rinvoq. In December 2021 there was another JAK inhibitors drug class safety development, with Xeljanz, Olumiant, … [Read more...]